Ignyta Inc. (NASDAQ:RXDX)’s share price traded down 2.3% during trading on Tuesday . The company traded as low as $5.50 and last traded at $5.53, with a volume of 84,872 shares trading hands. The stock had previously closed at $5.66.

A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Ignyta from a “hold” rating to a “sell” rating in a report on Saturday, August 13th. Piper Jaffray Cos. decreased their target price on Ignyta from $32.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Credit Suisse Group AG restated a “buy” rating on shares of Ignyta in a report on Tuesday, July 12th. JPMorgan Chase & Co. assumed coverage on Ignyta in a report on Thursday, June 23rd. They set an “overweight” rating and a $15.00 target price for the company. Finally, Cantor Fitzgerald restated a “buy” rating and set a $18.00 target price on shares of Ignyta in a report on Friday, June 17th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $16.36.

The stock’s market capitalization is $232.83 million. The stock has a 50-day moving average price of $5.69 and a 200-day moving average price of $6.37.

Ignyta (NASDAQ:RXDX) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.05. Analysts forecast that Ignyta Inc. will post ($2.83) EPS for the current year.

In related news, Director James A. Bristol bought 5,000 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was purchased at an average price of $5.65 per share, for a total transaction of $28,250.00. Following the acquisition, the director now owns 21,667 shares in the company, valued at $122,418.55. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Ignyta, Inc is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.